ECM Workshop

COPENHAGEN 18 - 19 APRIL 2018

Nordic Bioscience

Venue

Nordic Bioscience
Herlev Hovedgade 205-207
DK-2730 Herlev

Date
18 – 19 April 2018

Registration
13 April 2018

Abstract submission deadline
2 February 2018

Please send your abstract to
mk@nordicbio.com

Course fee for academia and course fee for industry will be announced

Please note: the programme is preliminary and subject to change.

----------

Nordic Bioscience is delighted to invite you to our first ECM Workshop.

The extra-cellular matrix (ECM) is receiving increased attention as a source of biomarkers for fibrotic, cancer and rheumatic disorders, but also as a source of drug targets. The biology and understanding of the ECM and how to quantify it, is a hot topic. Our research group has over 350 publications on the ECM and biomarkers.  We would like to encourage knowledge-sharing and research on ECM biology.

Therefore we will host a bi-yearly ECM & biomarker workshop in Copenhagen for two days. If you are interested in participating, please register by contacting Anna, at agd@nordicbio.com. The workshop will include perspectives on biomarker qualification and regulator interactions to advance the research on ECM biomarkers and precision medicine.

We look forward to seeing you in Copenhagen.

Morten Karsdal, CEO
Nordic Bioscience

---------- 

Preliminary Scientific Programme

Day 1

08:00 - 10:00
Introduction to the extra cellular matrix 
Morten A. Karsdal, PhD, Professor

  • The interstitial matrix – the components and function
  • The basement membrane – the components and function
  • The 28 collagens – introduction of the supra-structure and subtypes (the fantastic collagens)
  • The signaling potential of neo-epitopes – cause or consequence of disease
  • The proteoglycans of the ECM

10:00 - 10:15
Break

10:15 - 12:00
The ECM of the kidney
Federica Genovese, PhD

  • The structure and the ECM of the kidney
  • The ECM of the different subparts of the kidney, and their relation to kidney function and pathophysiology
  • The god standard biomarkers of the kidney
  • The collagen biomarkers of the kidney – prognostic, efficacy of intervention and diagnostic implications.
  • CKD – key data and need for future research.

12:00 - 12.30
Lunch

12:30 - 14:30
The ECM of the liver
Diana J Leeming, PhD

  • The structure and ECM of the liver  
  • The ECM of the different areas of the liver and the relation to liver function and pathophysiology
  • The gold standard biomarkers of the liver fibrosis
  • The activated fibroblast in liver fibrosis – the key collagens they produce
  • Spontanous phenotype  
  • The collagen biomarkers of the liver – prognostic, efficacy of intervention and diagnostic implications.
  • The key data of NAFLD/NASH, PSC, HEPC and alcoholic liver fibrosis

14:35 - 15:00
Session 1 | Abstract Oral Presentation
To be updated.

15:00 - 15:15
Break

15:15 - 16:30
The ECM of the lung
 Jannie Sand, PhD

  • The structure and ECM of the lung
  • The ECM of the different areas of the lung  and the relation to lung  function and pathophysiology
  • The god standard biomarkers of the COPD/IPF and Asthma   
  • The collagen biomarkers of the lung – prognostic, efficacy of intervention and diagnostic implications.
  • The key data of COPD, IPF and ASTMA – data from big cohorts with relation to exacerbations and lung function

16:30 - 18:00
Biomarkers in clinical development
Anne-Christine Bay Jensen, PhD

  • The BIPED classification
  • How to control the sampling – getting the best data controlling for the standard confounders in biomarker research
  • Examples of prediction of response  - doubling response of response rates
  • Examples of efficacy and diagnosis
  • How to ensure optimal assay quality – lessons learned from ELISA assay development focusing on precision and accuracy

18:00 - 18:25
Session 2 | Abstract Oral Presentation
To be updated.

20:00 - 22:00
Workshop Dinner

Day 2

08:00 - 10:00
Biomarker development and qualification in the eyes of EMA and FDA
Elisabeth Erhardtsen
 

  • Understanding the difference between PMN, PMA, and 510(k)
  • Understanding the enablement of biomarkers use in clinical development and patient selection by use of SRD, IDE and CTA.
  • Technical guidelines for FDA submissions
  • The main differences between FDA and EMA
  • Examples of different IVD tools accepted by the FDA.

10:00 - 10:15
Break

10:15 - 12:00
The ECM of the desmoplasia in cancers
Nicholas Willumsen, PhD

  • The desmolastic reaction in cancers
  • The IO – ECM interaction  
  • The basement membrane and intestinal matrix in cancers and relation function and pathophysiology
  • The gold standard biomarkers in cancers - is there one or is the liquid biopsy just fiction?
  • The collagen biomarkers for prediction of response and prognosis to provide optimal tools for treatment of patients
  • Can we find new and better treatments for cancer by modulating the ECM?

12:00 - 12.30
Lunch

12:30 - 14:30
SSC - The ECM of the skin
Anne-Sofie Siebuhr, PhD

  • The structure of the skin and the ECM of the skin
  • The multiple organ involvement in SSC
  • Collagen turnover in SSC – prognostic and diagnostic implications
  • The collagen – platelet axis in SSC
  • The gold standard biomarkers of the SSC
  • The collagen biomarkers of SSC – prognostic, efficacy of intervention and diagnostic implications.
  • SSC – key data and need for future research.

14:30 - 14:45
Break

14:45 - 16:00
IBD - The ECM of the intestine
Joachim Mortensen, PhD and Tina Manon-Jensen, PhD

  • IBD – UC and Chron’s – the ECM of the intestine
  • The basement membrane of the intestine; the high turnover tissue – is IBD more than just inflammation?
  • Gold standard biomarkers of IBD
  • The different tissue turnover rates of various tissues: Lung, liver, kidney, skin and intestine – the implications for biomarker research
  • Key ECM differences of UC and Chron’s and ECM biomarkers of IBD
  • Wound healing and mucosal wound healing and the relation to the ECM in IBD
  • The collagen-platelet axis in IBD                   
  • The collagen biomarkers of IBD – prognostic, efficacy of intervention and diagnostic implications
  • IBD – key data and need for future research.

16:00 - 16:25
Session 3 | Abstract Oral Presentation
To be updated.

16:30 - 18:00
Rheumatology - The ECM of the Joint
Christian Thudium, PhD

  • The ECM of the different components of the joint: Bone, cartilage and synovium
  • Ex vivo cultures of joint tissue and biomarkers – understanding the ECM turnover by assessment of formation and degradation ECM proteins
  • Diagnostic, efficacy of intervention biomarkers of bone, joint and synovium in OA, RA, PSA and AS
  • The tissue balance in rheumatology – relation to disease activity and tissue destruction
  • Prediction of response in rheumatology  
  • Translational science by use of ECM biomarkers.

18:00
Closing remarks